xoma
acquires
royalty
interest
four
lysosomal
storage
disorder
enzymes
developed
chiesi
strategic
alliance
emeryville
globe
newswire
xoma
corporation
nasdaq
xoma
announced
today
acquired
rights
future
milestone
royalty
revenue
due
bioasis
technologies
tsxv
otcqb
bioaf
associated
advancement
enzymes
investigated
potential
treatments
four
different
lysosomal
storage
disorders
lsd
bioasis
strategic
alliance
chiesi
group
bioasis
technology
designed
deliver
therapeutic
candidates
across
barrier
found
interesting
agreement
included
option
right
acquire
certain
royalty
rights
next
two
license
agreements
entered
bioasis
pleased
chiesi
group
pharmaceutical
company
driving
development
efforts
enzymes
rare
disease
indications
able
acquire
economic
position
commented
jim
neal
chief
executive
officer
xoma
enzyme
replacement
therapeutic
candidates
expand
xoma
royalty
interest
portfolio
beyond
monoclonal
antibodies
small
terms
agreement
exchange
million
upfront
payment
xoma
receive
low
royalty
future
net
sales
four
enzymes
undisclosed
share
million
potential
milestones
due
bioasis
agreement
chiesi
xoma
corporation
xoma
built
significant
portfolio
products
licensed
developed
biotechnology
pharmaceutical
companies
company
portfolio
programs
spans
multiple
stages
drug
development
process
across
various
therapeutic
areas
many
licenses
result
xoma
pioneering
efforts
discovery
development
antibody
therapeutics
company
business
model
includes
acquiring
additional
licenses
programs
information
visit
statements
certain
statements
contained
press
release
statements
within
meaning
section
securities
act
section
securities
exchange
act
including
statements
regarding
potential
xoma
portfolio
partnered
programs
licensed
technologies
generating
substantial
milestone
royalty
proceeds
time
creating
additional
value
stockholders
cash
sufficiency
forecast
economic
outlook
potential
impact
pandemic
statements
based
assumptions
may
prove
accurate
actual
results
could
differ
materially
anticipated
due
certain
risks
inherent
biotechnology
industry
including
related
fact
product
candidates
subject
agreements
still
developed
licensees
may
require
substantial
funds
continue
development
may
available
know
whether
continue
viable
market
products
ownership
royalty
interest
therapeutic
product
candidates
royalty
interest
receive
regulatory
approval
licensees
able
market
impact
global
economy
result
pandemic
potential
risks
xoma
meeting
expectations
described
detail
xoma
recent
filing
form
sec
filings
consider
risks
carefully
considering
xoma
prospects
statement
press
release
represents
xoma
views
date
press
release
relied
upon
representing
views
subsequent
date
xoma
disclaims
obligation
update
statement
except
required
applicable
law
explanatory
note
references
portfolio
press
release
refer
strictly
milestone
royalty
rights
associated
basket
drug
products
development
references
assets
press
release
refer
strictly
milestone
royalty
rights
associated
individual
drug
products
development
references
royalties
royalty
rates
strictly
refer
future
potential
payment
streams
regardless
whether
technically
defined
royalties
underlying
contractual
agreement
rates
referenced
herein
subject
potential
future
contractual
adjustments
date
press
release
assets
xoma
milestone
royalty
portfolio
investigational
compounds
efficacy
safety
established
guarantee
assets
become
commercially
available
investor
contact
juliane
snowden
oratorium
group
llc
jsnowden
media
contact
kathy
vincent
kv
consulting
management
kathy
